Smital Shah has over two decades of senior management experience in the biopharma and investment banking industries focused on financial strategy, capital markets, and business development. She currently has her own CFO/CBO advisory practice and consults with several biotech companies on finance/BD/operations strategy. She also served as board member and chair of the audit committees at Pliant Therapeutics and Graphite Bio. She was formerly chief business and financial officer of ProQR Therapeutics, a biotechnology company focused on rare genetic diseases. Previously, Ms. Shah managed the multi billion-dollar debt, cash, and investment portfolios of Gilead Sciences. Prior to Gilead, Ms. Shah spent several years in investment banking at Leerink Partners and JP Morgan focused on the biotech sector. Earlier in her career, she held various research and development positions at Johnson & Johnson. Ms. Shah has a bachelors and masters in chemical engineering and an MBA from the University of California, Berkeley.